Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 7 Treatment-related adverse events in patients with hepatocellular carcinoma, n (%)

Variable	Group		P value
	HBV-DNA > 2000, n = 54	HBV-DNA ≤ 2000, n = 66
Rash	4 (7)	6 (9)	> 0.999
Nausea	7 (13)	13 (20)	0.325
Diarrhea	5 (9)	5 (8)	0.752
Fatigue	4 (7)	6 (9)	> 0.999
Myocarditis	6 (11)	6 (9)	0.714
Hyperbilirubinemia	5 (9)	8 (12)	0.616
Hypertension	5 (9)	7 (11)	0.807
Leukopenia	6 (11)	8 (12)	0.864
Thrombocytopenia	7 (13)	10 (15)	0.732
RCCEP	23 (43)	31 (47)	0.632
Neutropenia	4 (7)	7 (11)	0.752
Proteinuria	14 (26)	18 (27)	0.868
Hypothyroidism	5 (9)	5 (8)	0.752
Elevated ALT	4 (7)	7 (11)	0.752
Elevated AST	7 (13)	6 (9)	0.497

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; RCCEP: Reactive cutaneous capillary endothelial proliferation; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.